EXPERIMENTAL STUDY OF ULCEROGENIC ACTION OF PROPOXAZEPAM


Keywords: benzodiazepines, propoxazepam, stomach mucous membrane, ulcerogenic action

Abstract

In experiments on 94 white male rats in the Wistar line, were studied changes in the gastric mucous under the acute, subchronic and chronic conditions after introduction of a new original derivative of benzodiazepine – proxazepam. The study of gastrotoxicity of propoxazepam was carried out under conditions of its intragastric administration with Tween-80 solvents and distilled water. It has been established that propoxazepam does not exhibit a damaging effect on the stomach in the conditions of acute (3 hours after, 50, 250, 500 and 1000 mg/kg perorally), as well as subacute (within 4 days, 50 mg/kg perorally) and chronic (within 28 days, 0,5 mg/kg perorally) administration, and also does not change the dietary behavior and general activity of animals, which is confirmation of harmlessness of this compound, in particular, on the gastrointestinal tract.

References

1. Benca, T. M. (2007). Porazhenie pishevaritelnoj sistemy nesteroidnymi protivovospalitelnymi preparatami. [The defeat of the digestive system with nonsteroidal anti-inflammatory drugs]. Racionalnaya farmakoterapiya – Rational pharmacotherapy, 4(5). Vzyato s http://rpt.health-ua.com/article/67.html.

2. Voloshchuk, N. I., Reder, A. S., Holovenko, M. Ya., Taran, I. V. & Pashynska, O. S. (2017). Farmakolohichnyi analiz neirokhimichnykh antynotsytseptyvnykh mekhanizmiv dii propoksazepamu. [Pharmacological analysis of neurochemical antinociceptive mechanisms of proxyxepam action]. Farmakolohiia ta likarska toksykolohiia – Pharmacology and drug toxicology, 1(53), 3–11.

3. Karateev, A. E. (2009). NPVP-associirovannaya patologiya verhnih otdelov ZhKT: sovremennye aspekty problemy. [NSAID-associated pathology of the upper gastrointestinal tract: modern aspects of the problem]. Vzyato s – Retrieved from http://medi.ru/doc/g421512.htm.

4. Kozhemiakin, Yu. M., Khromov, O. S., Filonenko, M. A. & Saifetdinova, H. A. (2002). Naukovo-praktychni rekomendatsii z utrymannia laboratornykh tvaryn ta roboty z nymy. [Scientific and practical recommendations for the maintenance of laboratory animals and work with them]. Derzhavnyi farmakolohichnyi tsentr MOZ Ukrainy. Kyiv – State Pharmacological Center of the Ministry of Health of Ukraine. Kiev.

5. Larionov, V. B. & Holovenko, M. Ya. (2017). Molekuliarnyi dokinh benzdiazepiniv – alosterychnykh moduliatoriv HAMK-retseptoru. [Molecular docking of benzodiazepines – alosteric modulators of the GABA receptor]. Farmakolohiia ta likarska toksykolohiia – Pharmacology and drug toxicology, 5(53), 38–49.

6. Nasonov, Ye. L. & Karateyev, A. Ye. (2000). Porazheniya zheludka, svyazannyye s priyemom nesteroidnykh protivovospalitel'nykh preparatov (chast' 1). [Lesions of the stomach associated with the use of non-steroidal anti-inflammatory drugs (part 1)]. Klinicheskaya meditsina – Clinical Medicine, 3, 4–7.

7. Reder, A. S., Andronati, S. A., Holovenko, M. YA., Pavlovsʹkyy, V. I., Kabanova, T. A., Khalimova, O. I., … Voloshchuk, N. I. (2017). Patent Ukrainy na vynakhid № 115205. [Patent of Ukraine for invention № 115205]. Kyiv: Derzhavne patentne vidomstvo Ukrainy – Kyiv: State Patent Office of Ukraine.

8. Ctepanov, Yu. M. & Breslavec, Yu. S. (2013). Dinamika soderzhaniya COG-2 v slizistoj zheludka i dvenadcatiperstnoj kishki na fone medikamentoznoj korrekcii NPVP-gastropatij. [Dynamics of COX-2 content in the stomach and duodenal mucosa on the background of drug-induced correction of NSAIDs-gastropathies]. Hastroenterolohii – Gastroenterology, 1, 24–27.

9. Stefanov, O. V. (Red.). (2001). Doklinichni doslidzhennia likarskykh zasobiv (metodychni rekomendatsii). [Preclinical research of medicinal products (methodical recommendations)]. Kyiv: Avitsena – Kiev: Avicenna.

10. Habriev, R. U. (Red). (2005). Rukovodstvo po eksperimentalnomu (doklinicheskomu) izucheniyu novyh farmakologicheskih veshestv. [Manual on experimental (preclinical) study of new pharmacological substances]. Moskva: OAO Izd-vo “Medicina” – Moscow: Public corporation Publishing house “Medicine”.

11. Brzozowski, T., Konturek, P. C., Konturek, S. J. Brzozowska, I. & Pawlik, T. (2005). Role of prostaglandins in gastroprotection and gastric adaptation. Journal of physiology and pharmacology, 56(5), 33–55.

12. Golovenko, N. Ya., Larionov, V. B., Reder, A. S. & Valivodz’, I. P. (2017). An effector analysis of the interaction of propoxazepam with antagonists of GABA and Glycine receptors. Neurochemical Journal, 11(4), 302–308. doi: 10.1134/S1819712417040043

13. Golovenko, N. Ya., Larionov, V. B., Reder, A. S., Voloshchuk, N. I., Valivodz, I. P. & Taran, I. V. (2016). GABA-ergic system activation by propyloxyderivative of 1,4-benzodiazepine in models of neuropathic pain and corazol-induced seizures. Journal NAMNU, 22(3-4), 318–24. doi: 10.2174/157015908783769653

14. Laine, L., Takeuchi, K. & Tarnawski, A. (2008) Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology, 135(1), 41–60. doi: 10.1053/j.gastro.2008.05.030.

15. Laporte, J., Ibanez, L. & Vidal, X. (2010). Upper gastrointestinal bleeding associated with the use of NSAIDs. Drug. Saf., 27, 411–420. DOI: 10.1111/j.1365-2036.2006.02759.x
Published
2018-08-08
How to Cite
Voloshchuk, N., ТaranІ., RederА., & Golovenko, M. (2018). EXPERIMENTAL STUDY OF ULCEROGENIC ACTION OF PROPOXAZEPAM. Reports of Vinnytsia National Medical University, 22(1), 6-9. https://doi.org/https://doi.org/10.31393/reports-vnmedical-2018-22(1)-01